Carmen Chang - Net Worth and Insider Trading

Carmen Chang Net Worth

The estimated net worth of Carmen Chang is at least $528 Million dollars as of 2024-11-29. Carmen Chang is the 10% Owner of Mirum Pharmaceuticals Inc and owns about 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) stock worth over $195 Million. Carmen Chang is the 10% Owner of Savara Inc and owns about 24,471,264 shares of Savara Inc (SVRA) stock worth over $85 Million. Carmen Chang is also the 10% Owner of MBX Biosciences Inc and owns about 3,614,486 shares of MBX Biosciences Inc (MBX) stock worth over $76 Million. Besides these, Carmen Chang also holds Korro Bio Inc (KRRO) , Akouos Inc (AKUS) , Trevi Therapeutics Inc (TRVI) , Coursera Inc (COUR) , Marker Therapeutics Inc (MRKR) , Regulus Therapeutics Inc (RGLS) , Metacrine Inc (MTCR) , Genocea Biosciences Inc (GNCAQ) . Details can be seen in Carmen Chang's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Carmen Chang has not made any transactions after 2024-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Carmen Chang

Carmen Chang Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Carmen Chang owns 15 companies in total, including Metacrine Inc (MTCR) , Genocea Biosciences Inc (GNCAQ) , and Akouos Inc (AKUS) among others .

Click here to see the complete history of Carmen Chang’s form 4 insider trades.

Insider Ownership Summary of Carmen Chang

Ticker	Comapny	Transaction Date	Type of Owner
MTCR	Metacrine Inc	2021-12-22	10 percent owner
GNCAQ	Genocea Biosciences Inc	2022-05-25	10 percent owner
AKUS	Akouos Inc	2020-06-30	10 percent owner
		2022-04-11	10 percent owner
		2020-01-29	10 percent owner
		2020-12-04	10 percent owner
		2019-07-22	10 percent owner
		2021-03-16	10 percent owner
		2018-06-01	10 percent owner
		2023-07-17	10 percent owner
		2023-03-15	director
		2021-06-24	10 percent owner
		2021-06-23	10 percent owner
		2018-06-01	10 percent owner
		2024-04-22	10 percent owner

Carmen Chang Latest Holdings Summary

Carmen Chang currently owns a total of 11 stocks. Among these stocks, Carmen Chang owns 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) as of July 22, 2019, with a value of $195 Million and a weighting of 36.99%. Carmen Chang owns 24,471,264 shares of Savara Inc (SVRA) as of July 17, 2023, with a value of $85 Million and a weighting of 16.08%. Carmen Chang also owns 3,614,486 shares of MBX Biosciences Inc (MBX) as of September 16, 2024, with a value of $76 Million and a weighting of 14.36%. The other 8 stocks Korro Bio Inc (KRRO) , Akouos Inc (AKUS) , Trevi Therapeutics Inc (TRVI) , Coursera Inc (COUR) , Marker Therapeutics Inc (MRKR) , Regulus Therapeutics Inc (RGLS) , Metacrine Inc (MTCR) , Genocea Biosciences Inc (GNCAQ) have a combined weighting of 32.57% among all his current holdings.

Latest Holdings of Carmen Chang

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MIRM	Mirum Pharmaceuticals Inc	2019-07-22	4,186,243	46.65	195,288,236
SVRA	Savara Inc	2023-07-17	24,471,264	3.47	84,915,286
MBX	MBX Biosciences Inc	2024-09-16	3,614,486	20.97	75,795,771
KRRO	Korro Bio Inc	2024-04-22	1,090,793	54.99	59,982,707
AKUS	Akouos Inc	2020-06-30	4,294,207	13.29	57,070,011
TRVI	Trevi Therapeutics Inc	2022-04-11	11,370,376	2.82	32,064,460
COUR	Coursera Inc	2023-03-15	2,237,523	8.20	18,347,689
MRKR	Marker Therapeutics Inc	2021-03-16	1,071,429	3.19	3,417,859
RGLS	Regulus Therapeutics Inc	2020-12-04	645,106	1.64	1,057,974
MTCR	Metacrine Inc	2021-12-22	2,563,257	0.00	3,589
GNCAQ	Genocea Biosciences Inc	2022-05-25	0	0.00	0

Holding Weightings of Carmen Chang

Carmen Chang Form 4 Trading Tracker

According to the SEC Form 4 filings, Carmen Chang has made a total of 0 transactions in Mirum Pharmaceuticals Inc (MIRM) over the past 5 years. The most-recent trade in Mirum Pharmaceuticals Inc is the acquisition of 450,000 shares on July 22, 2019, which cost Carmen Chang around $7 Million.

According to the SEC Form 4 filings, Carmen Chang has made a total of 1 transactions in Savara Inc (SVRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Savara Inc is the acquisition of 333,333 shares on July 17, 2023, which cost Carmen Chang around $999,999.

According to the SEC Form 4 filings, Carmen Chang has made a total of 1 transactions in MBX Biosciences Inc (MBX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in MBX Biosciences Inc is the acquisition of 500,000 shares on September 16, 2024, which cost Carmen Chang around $8 Million.

More details on Carmen Chang's insider transactions can be found in the Insider Trading History of Carmen Chang table.

Insider Trading History of Carmen Chang

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Carmen Chang Trading Performance

GuruFocus tracks the stock performance after each of Carmen Chang's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Carmen Chang is -1.55%. GuruFocus also compares Carmen Chang's trading performance to market benchmark return within the same time period. The performance of stocks bought by Carmen Chang within 3 months outperforms 5 times out of 13 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Carmen Chang's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Carmen Chang

Average Return

Average return per transaction

Outperforming Transactions

2 out of 12 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	2.78
Relative Return to S&P 500(%)	1.35

Carmen Chang Ownership Network

Ownership Network List of Carmen Chang

No Data

Ownership Network Relation of Carmen Chang

Carmen Chang Owned Company Details

What does Metacrine Inc do?

Who are the key executives at Metacrine Inc?

Carmen Chang is the 10 percent owner of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .

Metacrine Inc (MTCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metacrine Inc (MTCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metacrine Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Carmen Chang is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .

Genocea Biosciences Inc (GNCAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Carmen Chang is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Trevi Therapeutics Inc do?

Who are the key executives at Trevi Therapeutics Inc?

Carmen Chang is the 10 percent owner of Trevi Therapeutics Inc. Other key executives at Trevi Therapeutics Inc include director & 10 percent owner & See Remarks Jennifer L Good , director & 10 percent owner David P Meeker , and 10 percent owner & Chief Medical Officer Thomas Sciascia .

Trevi Therapeutics Inc (TRVI) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in Trevi Therapeutics Inc (TRVI). Other recent insider transactions involving Trevi Therapeutics Inc (TRVI) include a net sale of 7,825 shares made by Lisa Delfini , a net sale of 90,795 shares made by Jennifer L Good , and a net sale of 101,369 shares made by Thomas Sciascia .

In summary, during the past 3 months, insiders sold 61,180 shares of Trevi Therapeutics Inc (TRVI) in total and bought 0 shares, with a net sale of 61,180 shares. During the past 18 months, 204,544 shares of Trevi Therapeutics Inc (TRVI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 204,544 shares.

Trevi Therapeutics Inc (TRVI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Trevi Therapeutics Inc Insider Transactions

No Available Data

What does Black Diamond Therapeutics Inc do?

Who are the key executives at Black Diamond Therapeutics Inc?

Carmen Chang is the 10 percent owner of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , 10 percent owner Biotech Growth N V , and director & 10 percent owner Ali Behbahani .

Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net purchase of 3,140,000 shares made by Biotech Growth N V , a net purchase of 1,000,000 shares made by Ali Behbahani , and a net purchase of 935,850 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 246,600 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 5,075,850 shares were bought by its insiders, resulting in a net purchase of 4,829,250 shares.

Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Black Diamond Therapeutics Inc Insider Transactions

No Available Data

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Carmen Chang is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Financial Officer Crispina Calsada , Sr. VP & General Counsel Christopher Ray Aker , and Chief Operating Officer Joseph P Hagan .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regulus Therapeutics Inc Insider Transactions

No Available Data

What does Mirum Pharmaceuticals Inc do?

Who are the key executives at Mirum Pharmaceuticals Inc?

Carmen Chang is the 10 percent owner of Mirum Pharmaceuticals Inc. Other key executives at Mirum Pharmaceuticals Inc include SVP & Global Controller Jolanda Howe , director & 10 percent owner Patrick J Heron , and Chief Scientific Officer Pamela Vig .

Mirum Pharmaceuticals Inc (MIRM) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in Mirum Pharmaceuticals Inc (MIRM). Other recent insider transactions involving Mirum Pharmaceuticals Inc (MIRM) include a net sale of 11,012 shares made by Jolanda Howe , a net purchase of 162,308 shares made by Patrick J Heron , and a net sale of 34,606 shares made by Pamela Vig .

In summary, during the past 3 months, insiders sold 2,500 shares of Mirum Pharmaceuticals Inc (MIRM) in total and bought 345 shares, with a net sale of 2,155 shares. During the past 18 months, 108,350 shares of Mirum Pharmaceuticals Inc (MIRM) were sold and 176,308 shares were bought by its insiders, resulting in a net purchase of 67,958 shares.

Mirum Pharmaceuticals Inc (MIRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirum Pharmaceuticals Inc Insider Transactions

No Available Data

What does Marker Therapeutics Inc do?

Who are the key executives at Marker Therapeutics Inc?

Carmen Chang is the 10 percent owner of Marker Therapeutics Inc. Other key executives at Marker Therapeutics Inc include Interim CFO Eliot M Lurier , 10 percent owner Mohamad Makhzoumi , and 10 percent owner New Enterprise Associates 16, L.p. .

Marker Therapeutics Inc (MRKR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Marker Therapeutics Inc (MRKR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Marker Therapeutics Inc (MRKR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Marker Therapeutics Inc (MRKR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marker Therapeutics Inc Insider Transactions

No Available Data

What does X4 Pharmaceuticals Inc do?

Who are the key executives at X4 Pharmaceuticals Inc?

Carmen Chang is the 10 percent owner of X4 Pharmaceuticals Inc. Other key executives at X4 Pharmaceuticals Inc include director & President and CEO Paula Ragan , Chief Scientific Officer Arthur Taveras , and Chief Operating Officer Mary Dibiase .

X4 Pharmaceuticals Inc (XFOR) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in X4 Pharmaceuticals Inc (XFOR). Other recent insider transactions involving X4 Pharmaceuticals Inc (XFOR) include a net sale of 633,780 shares made by Paula Ragan , a net sale of 161,480 shares made by Mary Dibiase , and a net sale of 552,345 shares made by Adam S. Mostafa .

In summary, during the past 3 months, insiders sold 692,259 shares of X4 Pharmaceuticals Inc (XFOR) in total and bought 0 shares, with a net sale of 692,259 shares. During the past 18 months, 1,658,682 shares of X4 Pharmaceuticals Inc (XFOR) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 1,633,682 shares.

X4 Pharmaceuticals Inc (XFOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

X4 Pharmaceuticals Inc Insider Transactions

No Available Data

What does Savara Inc do?

Who are the key executives at Savara Inc?

Carmen Chang is the 10 percent owner of Savara Inc. Other key executives at Savara Inc include Chief Financial Officer David L Lowrance , 10 percent owner Rick Yang , and 10 percent owner Scott D Sandell .

Savara Inc (SVRA) Insider Trades Summary

Over the past 18 months, Carmen Chang made 1 insider transaction in Savara Inc (SVRA) with a net purchase of 333,333. Other recent insider transactions involving Savara Inc (SVRA) include a net purchase of 333,333 shares made by Growth Equity Opportunities 17, Llc , a net purchase of 333,333 shares made by Scott D Sandell , and a net purchase of 333,333 shares made by Mohamad Makhzoumi .

In summary, during the past 3 months, insiders sold 0 shares of Savara Inc (SVRA) in total and bought 120,000 shares, with a net purchase of 120,000 shares. During the past 18 months, 187,843 shares of Savara Inc (SVRA) were sold and 3,459,830 shares were bought by its insiders, resulting in a net purchase of 3,271,987 shares.

Savara Inc (SVRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Savara Inc Insider Transactions

No Available Data

What does Coursera Inc do?

Who are the key executives at Coursera Inc?

Carmen Chang is the director of Coursera Inc. Other key executives at Coursera Inc include SVP & General Counsel Alan B Cardenas , See Remarks Richard J Jacquet , and director & See Remarks Jeffrey Nacey Maggioncalda .

Coursera Inc (COUR) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in Coursera Inc (COUR). Other recent insider transactions involving Coursera Inc (COUR) include a net sale of 1,710,001 shares made by Jeffrey Nacey Maggioncalda , a net sale of 473,099 shares made by Shravan Goli , and a net sale of 892,582 shares made by Andrew Y. Ng .

In summary, during the past 3 months, insiders sold 13,885 shares of Coursera Inc (COUR) in total and bought 0 shares, with a net sale of 13,885 shares. During the past 18 months, 3,835,478 shares of Coursera Inc (COUR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,835,478 shares.

Coursera Inc (COUR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Coursera Inc Insider Transactions

No Available Data

What does NeueHealth Inc do?

Who are the key executives at NeueHealth Inc?

Carmen Chang is the 10 percent owner of NeueHealth Inc. Other key executives at NeueHealth Inc include Chief Financial Officer Jay Matushak , Chief Accounting Officer Jeffrey J Scherman , and director & CEO and President Mikan George Lawrence Iii .

NeueHealth Inc (NEUE) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in NeueHealth Inc (NEUE). Other recent insider transactions involving NeueHealth Inc (NEUE) include a net sale of 3,494 shares made by Jay Matushak , a net sale of 56,739 shares made by Mikan George Lawrence Iii , and a net sale of 1,436 shares made by Jeffrey J Scherman .

In summary, during the past 3 months, insiders sold 87 shares of NeueHealth Inc (NEUE) in total and bought 0 shares, with a net sale of 87 shares. During the past 18 months, 65,750 shares of NeueHealth Inc (NEUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 65,750 shares.

NeueHealth Inc (NEUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeueHealth Inc Insider Transactions

No Available Data

What does Monte Rosa Therapeutics Inc do?

Who are the key executives at Monte Rosa Therapeutics Inc?

Carmen Chang is the 10 percent owner of Monte Rosa Therapeutics Inc. Other key executives at Monte Rosa Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , Principal Accounting Officer Edmund Dunn , and General Counsel Philip Nickson .

Monte Rosa Therapeutics Inc (GLUE) Insider Trades Summary

Over the past 18 months, Carmen Chang made no insider transaction in Monte Rosa Therapeutics Inc (GLUE). Other recent insider transactions involving Monte Rosa Therapeutics Inc (GLUE) include a net sale of 1,857,674 shares made by Versant Venture Capital Vi, L.p. , and a net sale of 2,817 shares made by Edmund Dunn .

In summary, during the past 3 months, insiders sold 1,857,674 shares of Monte Rosa Therapeutics Inc (GLUE) in total and bought 0 shares, with a net sale of 1,857,674 shares. During the past 18 months, 1,860,491 shares of Monte Rosa Therapeutics Inc (GLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,860,491 shares.

Monte Rosa Therapeutics Inc (GLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Monte Rosa Therapeutics Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Carmen Chang is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , EVP PHARM SCI & MFG Stapleton Raymond D Jr , and 10 percent owner Paul Edward Walker .

Genocea Biosciences Inc (GGNNQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GGNNQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GGNNQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GGNNQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does Korro Bio Inc do?

Who are the key executives at Korro Bio Inc?

Carmen Chang is the 10 percent owner of Korro Bio Inc. Other key executives at Korro Bio Inc include Chief Financial Officer Vineet Agarwal , 10 percent owner Scott D Sandell , and 10 percent owner New Enterprise Associates 17, L.p. .

Korro Bio Inc (KRRO) Insider Trades Summary

Over the past 18 months, Carmen Chang made 1 insider transaction in Korro Bio Inc (KRRO) with a net purchase of 17,857. Other recent insider transactions involving Korro Bio Inc (KRRO) include a net sale of 11,016 shares made by Vineet Agarwal , a net sale of 2,124 shares made by David L. Lucchino , and a net purchase of 17,857 shares made by Edward T Mathers .

In summary, during the past 3 months, insiders sold 11,016 shares of Korro Bio Inc (KRRO) in total and bought 0 shares, with a net sale of 11,016 shares. During the past 18 months, 13,140 shares of Korro Bio Inc (KRRO) were sold and 178,570 shares were bought by its insiders, resulting in a net purchase of 165,430 shares.

Korro Bio Inc (KRRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Korro Bio Inc Insider Transactions

No Available Data

Carmen Chang Mailing Address

Above is the net worth, insider trading, and ownership report for Carmen Chang. You might contact Carmen Chang via mailing address: 2855 Sand Hill Road, Menlo Park Ca 94025.

Discussions on Carmen Chang

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.